Literature DB >> 9201374

Leukotriene E4 plasma levels in adult asthmatic patients with variable disease severity.

C Chavis1, T van Vyve, P Chanez, M Farce, J Bousquet, F B Michel, P Godard.   

Abstract

Cysteinyl leukotrienes (C-LTs) are local inflammatory mediators involved in bronchial asthma. Seventeen asthmatic patients (FEV1 ranging from 41 to 99.8% of predicted values) and 11 healthy subjects were studied. The clinical severity of asthma was assessed by the Aas score. Plasma C-LTs were measured by enzyme immunoassay (EIA) after sample purification by solid-phase extraction (SPE), to investigate whether differences may exist between asthmatic and control subjects and whether leukotriene E4 (LTE4) levels were related to the severity of disease. LT measurements showed that 87.6 +/- 1.2% was recovered as LTE4 and 9.4 +/- 1.3% as LTC4. In asthmatic subjects, LTE4 plasma levels were found to be significantly higher than those in the control group (1.073 +/- 0.133 and 0.53 +/- 0.19 ng/ml of plasma, respectively; P < 0.002). Moreover, there was a significant correlation between LTE4 plasma levels and the Aas clinical score (P < 0.005). These data suggest that plasma LTE4 levels might be used to assess the severity of asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201374     DOI: 10.1111/j.1398-9995.1997.tb02606.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  5 in total

Review 1.  Anti-leukotrienes in asthma: yet to arrive.

Authors:  G Gupta
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

2.  Anti-leukotrienes in Childhood Asthma.

Authors:  Girish Gupta; S K Jatana; C G Wilson
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients.

Authors:  P Cáp; J Chládek; F Pehal; M Malý; V Petrů; P J Barnes; P Montuschi
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

4.  Phase 2 trial of montelukast for prevention of pain in sickle cell disease.

Authors:  Joshua J Field; Adetola Kassim; Amanda Brandow; Stephen H Embury; Neil Matsui; Karina Wilkerson; Valencia Bryant; Liyun Zhang; Pippa Simpson; Michael R DeBaun
Journal:  Blood Adv       Date:  2020-03-24

5.  Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors.

Authors:  O Demin; T Karelina; D Svetlichniy; E Metelkin; G Speshilov; O Demin; D Fairman; P H van der Graaf; B M Agoram
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-09-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.